1. Bray F, Ferlay J, Soerjomataram Iet al., "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA Cancer J Clin, vol.68, no.6, pp.394-424, 2018
2. Siegel RL, Miller KD, Fuchs HE, Jemal A, "Cancer Statistics, 2021," CA Cancer J Clin, vol.71, no.1, pp.7-33, 2021
3. Hassan O, Han M, Zhou Aet al., "Incidence of Extraprostatic Extension at Radical Prostatectomy with Pure Gleason Score 3 + 3 = 6 (Grade Group 1) Cancer: Implications for Whether Gleason Score 6 Prostate Cancer Should be Renamed "Not Cancer" and for Selection Criteria for Active Surveillance," J Urol, vol.199, no.6, pp.1482-1487, 2018
4. Sato S, Kimura T, Yorozu Tet al., "Cases Having a Gleason Score 3+4=7 With <5% of Gleason Pattern 4 in Prostate Needle Biopsy Show Similar Failure-free Survival and Adverse Pathology Prevalence to Gleason Score 6 Cases in a Radical Prostatectomy Cohort," Am J Surg Pathol, vol.43, no.11, pp.1560-1565, 2019
5. Stolzenbach LF, Rosiello G, Pecoraro Aet al., "Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White Patients," J Natl Compr Canc Netw, vol.18, no.11, pp.1492-1499, 2020
6. Butler S, Muralidhar V, Chavez Jet al., "Active Surveillance for Low-Risk Prostate Cancer in Black Patients," N Engl J Med, vol.380, no.21, pp.2070-2072, 2019
7. Nelson JB, "The Ongoing Challenge of Urinary Incontinence after Radical Prostatectomy," J Urol, vol.198, no.6, pp.1223-1225, 2017
8. Kirschner-Hermanns R, Jakse G, "Quality of life following radical prostatectomy," Crit Rev Oncol Hematol, vol.43, no.2, pp.141-151, 2002
9. Hamdy FC, Donovan JL, Lane JAet al., "10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer," N Engl J Med, vol.375, no.15, pp.1415-1424, 2016
10. Tosoian JJ, Mamawala M, Epstein JIet al., "Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer," J Clin Oncol, vol.33, no.30, pp.3379-3385, 2015
11. Klotz L, Vesprini D, Sethukavalan Pet al., "Long-term follow-up of a large active surveillance cohort of patients with prostate cancer," J Clin Oncol, vol.33, no.3, pp.272-277, 2015
12. Faisal FA, Sundi D, Tosoian JJet al., "Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location," Eur Urol, vol.70, no.1, pp.14-17, 2016
13. Singh S, Patil S, Tamhankar AS, Ahluwalia P, Gautam G, "Low-risk prostate cancer in India: Is active surveillance a valid treatment option?," Indian J Urol, vol.36, no.3, pp.184-190, 2020
14. Jeon HG, Yoo JH, Jeong BCet al., "Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance," PLoS One, vol.12, no.11, pp.e0186026, 2017
15. Kim TH, Jeon HG, Choo SHet al., "Pathological upgrading and upstaging of patients eligible for active surveillance according to currently used protocols," Int J Urol, vol.21, no.4, pp.377-381, 2014
16. Iremashvili V, Pelaez L, Manoharan Met al., "Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols," Eur Urol, vol.62, no.3, pp.462-468, 2012
17. van Houten ME, Gooren LJ, "Differences in reproductive endocrinology between Asian men and Caucasian men--a literature review," Asian J Androl, vol.2, no.1, pp.13-20, 2000
18. Pompe RS, Davis-Bondarenko H, Zaffuto Eet al., "Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment," Prostate, vol.77, no.6, pp.686-693, 2017
19. Druskin SC, Mamawala M, Tosoian JJet al., "Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance," J Urol, vol.201, no.1, pp.98-104, 2019
20. Gershman B, Dahl DM, Olumi AFet al., "Smaller prostate gland size and older age predict Gleason score upgrading," Urol Oncol, vol.31, no.7, pp.1033-1037, 2013
21. Verep S, Erdem S, Ozluk Yet al., "The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?," Prostate, vol.79, no.13, pp.1523-1529, 2019
22. Camur E, Coskun A, Kavukogluet al., "Prostate volume effect on Gleason score upgrading in active surveillance appropriate patients," Arch Ital Urol Androl, vol.91, no.2, 2019
23. Jin BS, Kang SH, Kim DYet al., "Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?," Korean J Urol, vol.56, no.9, pp.624-629, 2015
24. Wegelin O, van Melick HHE, Hooft Let al., "Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique?," Eur Urol, vol.71, no.4, pp.517-531, 2017
25. Emmett L, Buteau J, Papa Net al., "The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study," Eur Urol, 2021
26. Lim DW, Giannakeas V, Narod SA, "Survival Differences in Chinese Versus White Women With Breast Cancer in the United States: A SEER-Based Analysis," JCO Glob Oncol, vol.6, pp.1582-1592, 2020